A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer

Trial Profile

A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel; Paclitaxel; Vinflunine
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-045
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Results (n=525) of a subgroup analysis evaluating pembrolizumab versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer, presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Sep 2017 Updated results from this trial have been presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 10 Sep 2017 Updated results published in a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top